Skip to main content

Recombinant Human IFN-alpha/beta R2 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 4015-AB

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
4015-AB-050

Key Product Details

Source

NS0

Accession #

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human IFN-alpha/beta R2 protein
Human IFN-alpha / beta R2
(Ile27-Lys243)
Accession # P48551
IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ile27

Predicted Molecular Mass

51.3 kDa (monomer)

SDS-PAGE

71-76 kDa, reducing conditions

Activity

Measured by its ability to inhibit Type-I IFN-mediated anti-viral activity.
The ED50 for this effect, as measured by inhibition of Recombinant Human IFN‑ beta (Catalog # 8499-IF) , is 0.1-0.6 μg/mL

Scientific Data Images for Recombinant Human IFN-alpha/beta R2 Fc Chimera Protein, CF

Recombinant Human IFN-alpha/beta R2 Fc Chimera Protein Bioactivity

Recombinant Human IFN-alpha/beta R2 Fc Chimera Protein Bioactivity

Recombinant Human IFN-alpha/beta R2 Fc Chimera (Catalog # 4015-AB) inhibits the anti-viral activity of Recombinant Human IFN-beta (Catalog # 8499-IF). The ED50 for this effect is 0.1-0.6 μg/mL.

Formulation, Preparation and Storage

4015-AB
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 500 μg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IFN-alpha/beta R2

IFN-alpha / beta R2, also known as IFNAR2, is a 100 kDa glycoprotein in the class II cytokine receptor family. These proteins form heterodimeric receptor complexes that transduce signals from the interferon, IL-10, and IL-28 families of cytokines (1, 2). IFN-alpha / beta R2, in association with IFN-alpha / beta R1, is required for mediating the antiviral, antiproliferative, and apoptotic effects of the type I interferons IFN-alpha and IFN-beta. IFN-alpha / beta R2 is the principal ligand binding subunit of the receptor. Ligand binding is stabilized by the subsequent association with IFN-alpha / beta R1, resulting in the formation of a signaling ternary receptor complex (3, 4). Mature human IFN-alpha / beta R2 consists of a 217 amino acid (aa) extracellular domain (ECD) with two fibronectin type III repeats, a 21 aa transmembrane segment, and a 251 aa cytoplasmic domain. Alternate splicing generates a secreted isoform that corresponds to the ECD and a 50 kDa transmembrane isoform with a substituted and truncated cytoplasmic region (5, 6). The short isoform is impaired in its ability to activate signaling molecules and functions as a dominant negative receptor subunit (7 - 9). IFN-alpha / beta R2 is also subject to presenilin-dependent intramembrane proteolysis, resulting in the liberation of nearly the entire ECD as well as the cytoplasmic domain which migrates to the nucleus and can inhibit gene transcription (10). High concentrations of soluble IFN-alpha / beta R2 bind and neutralize IFN-alpha and IFN-beta, while lower concentrations prolong the antiviral activity of circulating IFN-beta but not IFN-alpha (11). Human but not mouse IFN-alpha / beta R2 constitutively associates with STAT4, which may account for species specific differences observed in type I interferon responses (12). Within the ECD, human IFN-alpha / beta R2 shares 63%, 60%, and 48% aa sequence identity with bovine, mouse, and ovine IFN-alpha / beta R2, respectively.

References

  1. Langer, J.A. et al. (2004) Cytokine Growth Factor Rev. 15:33.
  2. Pestka, S. et al. (2004) Immunol. Rev. 202:8.
  3. Lamken, P. et al. (2004) J. Mol. Biol. 341:303.
  4. Arduini, R.M. et al. (1999) Prot. Sci. 8:1867.
  5. Lutfalla, G. et al. (1995) EMBO J. 14:5100.
  6. Novick, D. et al. (1995) J. Leukocyte Biol. 57:712.
  7. Pfeffer, L.M. et al. (1997) J. Biol. Chem. 272:11002.
  8. Gazziola, C. et al. (2005) Int. J. Oncol. 26:129.
  9. Kotenko, S.V. and S. Pestka (2000) Oncogene 19:2557.
  10. Saleh, A.Z.M. et al. (2004) Oncogene 23:7076.
  11. McKenna, S.D. et al. (2004) J. Interferon Cytokine Res. 24:119.
  12. Tyler, D.R. et al. (2007) Mol. Immunol. 44:1864.

Long Name

Interferon alpha/beta Receptor 2

Alternate Names

IFN-aR2, IFN-bR2, IFNAR2, IFNbR2

Entrez Gene IDs

3455 (Human); 15976 (Mouse); 102140083 (Cynomolgus Monkey)

Gene Symbol

IFNAR2

UniProt

Additional IFN-alpha/beta R2 Products

Product Documents for Recombinant Human IFN-alpha/beta R2 Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human IFN-alpha/beta R2 Fc Chimera Protein, CF

For research use only

Loading...
Loading...
Loading...